Biosimulation Market: AI, Model-Informed Drug Development & Future Growth Outlook to 2031

Biosimulation Market Overview

The global Biosimulation Market is rapidly evolving as pharmaceutical and biotechnology companies increasingly use computational modeling and simulation to improve drug discovery, development, and clinical decision-making.

According to MarketsandMarkets™, the global biosimulation market is projected to grow from approximately USD 4.27 billion in 2026 to USD 9.24 billion by 2031, registering a CAGR of 16.7% during 2026–2031.

The increasing complexity of drug development, growing adoption of model-informed drug development (MIDD), integration of artificial intelligence, and pressure to reduce R&D costs and timelines are among the key factors supporting market expansion.

Download PDF Brochure

Biosimulation Market at a Glance

Market IndicatorValue
Market Size, 2025—
Market Size, 2026USD 4.27 billion
Projected Market Size, 2031USD 9.24 billion
CAGR, 2026–203116.7%
Largest Offering, 2025Software
Software Market Share, 202562.8%
Fastest-Growing Development PhaseEarly clinical development
Leading Region, 2025North America
North America Market Share, 202548.0%
Fastest-Growing RegionAsia Pacific

What Is Biosimulation?

Biosimulation refers to the use of computational models and simulations to represent biological systems, drug behavior, disease processes, and treatment responses.

These technologies enable researchers to evaluate different scenarios virtually before conducting expensive laboratory or clinical experiments.

Major biosimulation approaches include:

  • Physiologically based pharmacokinetic (PBPK) modeling
  • Quantitative systems pharmacology (QSP)
  • Pharmacometrics
  • Molecular modeling
  • Computational chemistry
  • Molecular dynamics
  • Virtual patient simulations
  • Exposure-response modeling

By providing computational insights into drug behavior, biosimulation can help researchers make better-informed decisions throughout the drug development lifecycle.

Key Factors Driving the Biosimulation Market

1. Increasing Complexity of Drug Development

Modern drug development is becoming increasingly complex because of the emergence of biologics, advanced therapies, personalized medicine, and increasingly sophisticated disease models.

Researchers need to evaluate multiple variables related to drug exposure, efficacy, safety, patient characteristics, and disease progression.

Biosimulation enables these variables to be analyzed computationally, helping researchers understand potential outcomes before committing significant resources to experimental studies.

2. Growing Adoption of Model-Informed Drug Development

Model-informed drug development (MIDD) is becoming an increasingly important approach in pharmaceutical R&D.

MIDD integrates mathematical and computational models with experimental and clinical data to support decisions regarding:

  • Candidate selection
  • Dose optimization
  • Clinical trial design
  • Patient selection
  • Drug exposure
  • Safety assessment
  • Regulatory submissions

The growing acceptance of MIDD is consequently creating strong demand for biosimulation software and specialized modeling services.

3. Integration of Artificial Intelligence

AI and machine learning are increasingly being incorporated into biosimulation workflows.

AI can help researchers process large datasets, identify complex relationships, optimize models, and generate predictions more efficiently.

The convergence of AI + biosimulation could significantly accelerate computational drug discovery and development by combining data-driven approaches with mechanistic biological models.

Software Segment Dominates the Market

By offering, the biosimulation market is segmented into software and services.

The software segment dominated the market with a 62.8% share in 2025.

Biosimulation software enables researchers to construct, run, analyze, and validate complex biological and pharmacological models.

These platforms are used for applications ranging from pharmacokinetic modeling to molecular simulation and quantitative systems pharmacology.

However, the services segment is expected to grow at a faster rate than software during the forecast period.

Request Sample Pages

Why Biosimulation Services Are Growing

Many pharmaceutical and biotechnology companies, particularly small and medium-sized organizations, may not have specialized internal expertise in advanced computational modeling.

As a result, they increasingly rely on external providers for:

  • PBPK modeling
  • QSP modeling
  • Pharmacometrics
  • Model validation
  • Regulatory modeling
  • Data analysis
  • Strategic consulting
  • Clinical trial simulation

The increasing complexity of biosimulation workflows and integration of AI and advanced analytics are further increasing demand for specialized expertise.

For smaller biopharmaceutical companies, outsourcing can provide access to specialized computational capabilities without requiring substantial investment in internal infrastructure and personnel.

Early Clinical Development Is a High-Growth Opportunity

By phase of development, the early clinical development segment is expected to register the highest CAGR during the forecast period.

Biosimulation can support early clinical development by helping researchers evaluate drug exposure, dose-response relationships, safety margins, and potential patient variability.

Computational models can be used to inform dose selection and clinical study design before or alongside clinical experimentation.

This can potentially help pharmaceutical companies make faster development decisions and reduce unnecessary trial-and-error.

On-Premises Deployment Leads the Market

By deployment mode, on-premises solutions accounted for the largest market share in 2025.

Pharmaceutical and biotechnology companies frequently manage highly sensitive datasets involving:

  • Proprietary drug candidates
  • Preclinical data
  • Clinical data
  • Molecular information
  • Intellectual property
  • Regulatory information

Consequently, organizations often prioritize data security, governance, and control when selecting biosimulation infrastructure.

Large pharmaceutical companies have also invested in high-performance computing (HPC) environments to support computationally intensive applications such as molecular dynamics, computational chemistry, PBPK modeling, QSP, and AI-assisted drug discovery.

However, cloud-based biosimulation is expected to gain increasing attention as organizations seek scalability, collaboration, and flexible computational resources.

North America Leads the Biosimulation Market

North America accounted for approximately 48.0% of the global biosimulation market in 2025, making it the largest regional market.

The region’s leadership is supported by:

  • Strong pharmaceutical and biotechnology industries
  • High R&D expenditure
  • Advanced computational infrastructure
  • Strong presence of biosimulation companies
  • Growing adoption of MIDD
  • Increasing use of AI in drug discovery
  • Established regulatory and research ecosystems

The US remains a major contributor to regional growth because of its concentration of pharmaceutical companies, biotechnology firms, CROs, academic institutions, and technology providers.

Asia Pacific Is the Fastest-Growing Region

While North America currently dominates the market, Asia Pacific is projected to be the fastest-growing regional market during the forecast period.

Countries including China, India, Japan, South Korea, and Singapore are strengthening their pharmaceutical and biotechnology ecosystems.

Several factors are supporting regional growth:

  • Increasing pharmaceutical R&D investment
  • Expansion of biotechnology
  • Growing drug discovery capabilities
  • Government-supported research initiatives
  • Expanding biopharmaceutical manufacturing
  • Increasing AI adoption
  • Growth of CROs
  • Demand for cost-efficient drug development

The expansion of global pharmaceutical companies and research organizations across Asia Pacific is also expected to increase demand for computational modeling and simulation technologies.

Biosimulation in Precision Medicine

Precision medicine is another important opportunity for biosimulation.

Traditional drug development often relies on population-level averages, whereas precision medicine seeks to understand how treatments may behave differently across individual patients.

Biosimulation can incorporate patient-specific characteristics to model potential treatment outcomes.

This can support:

  • Personalized dosing
  • Patient stratification
  • Treatment-response prediction
  • Clinical trial optimization
  • Safety assessment

The increasing availability of real-world and patient-level data could further enhance the capabilities of personalized biosimulation.

Biosimulation and Biologics

The expansion of biologics is creating new requirements for computational modeling.

Biologics can exhibit complex pharmacokinetic and pharmacodynamic behavior, making computational approaches valuable for understanding drug exposure and response.

Biosimulation can support development of:

  • Monoclonal antibodies
  • Therapeutic proteins
  • Biosimilars
  • Cell therapies
  • Gene therapies

As advanced therapies become increasingly important in pharmaceutical pipelines, biosimulation is expected to play a larger role in their development.

Role of Biosimulation in Reducing Drug Development Costs

Drug development is expensive and time-consuming, with significant uncertainty throughout the R&D process.

Biosimulation can help reduce some of this uncertainty by allowing researchers to test hypotheses computationally.

Potential benefits include:

  • Earlier identification of promising candidates
  • Improved dose selection
  • Better clinical trial design
  • Reduced experimental iterations
  • More efficient use of clinical data
  • Improved understanding of patient variability

Although biosimulation does not replace experimental or clinical research, it can complement traditional approaches and improve decision-making.

AI and Biosimulation: The Next Frontier

The convergence of artificial intelligence and biosimulation is expected to become one of the most important technology trends in the market.

AI can assist with:

Model development: Machine learning can help identify relationships within complex datasets.

Parameter optimization: AI can support faster calibration and optimization of computational models.

Prediction: Data-driven algorithms can generate predictions regarding drug response and biological behavior.

Simulation acceleration: Advanced computational methods can reduce the time required to evaluate complex scenarios.

The combination of mechanistic models and AI-based methods could create more powerful tools for pharmaceutical R&D.

Major Applications of Biosimulation

Biosimulation technologies are increasingly being applied across several stages of drug development.

Drug Discovery

Computational chemistry and molecular modeling can help identify and optimize promising drug candidates.

Preclinical Development

PBPK and pharmacometric models can support understanding of drug exposure and biological behavior.

Clinical Development

Simulation can help optimize dosing strategies, trial designs, and patient populations.

Regulatory Applications

Validated models can provide additional evidence to support regulatory decision-making in appropriate contexts.

Personalized Medicine

Patient-specific models can help evaluate variability in drug response and support individualized treatment strategies.

Challenges Facing the Biosimulation Market

Despite strong growth opportunities, several challenges remain.

Model Validation

The reliability of biosimulation depends heavily on the quality and validation of computational models.

Data Quality

Poor-quality, incomplete, or inconsistent data can reduce model accuracy.

Regulatory Complexity

The increasing use of computational models in regulatory decision-making requires appropriate standards and validation frameworks.

Shortage of Specialized Expertise

Advanced biosimulation requires multidisciplinary expertise spanning biology, pharmacology, mathematics, computational science, and data analytics.

Integration Challenges

Integrating biosimulation platforms with existing R&D systems and datasets can be technically complex.

Competitive Landscape

The biosimulation market includes specialized software developers, computational science companies, and service providers.

Major companies include:

  • Certara (US)
  • Dassault Systèmes (France)
  • Schrödinger, Inc. (US)
  • Simulations Plus (US)
  • Advanced Chemistry Development, Inc. (Revvity) (Canada)
  • Chemical Computing Group ULC (Canada)

These companies are focusing on software development, computational modeling, simulation services, AI integration, molecular modeling, pharmacometrics, and regulatory support.

Future Outlook

The future of the biosimulation market will be defined by the convergence of AI, mechanistic modeling, high-performance computing, cloud technology, precision medicine, and model-informed drug development.

As pharmaceutical pipelines become more complex, companies will increasingly need computational tools capable of integrating biological, clinical, molecular, and patient-level data.

The continued growth of biologics, cell and gene therapies, and personalized medicine is expected to further expand the role of biosimulation.

At the same time, increasing regulatory acceptance of validated computational models could accelerate their integration into drug development workflows.

Conclusion

The global Biosimulation Market is positioned for significant growth, increasing from USD 4.27 billion in 2026 to USD 9.24 billion by 2031, at a CAGR of 16.7%.

The market is being driven by growing drug development complexity, increasing adoption of MIDD, rising use of AI in life-science R&D, and the need to improve pharmaceutical R&D productivity.

Software currently dominates the market, while biosimulation services are expected to grow at a faster rate. North America remains the largest regional market, while Asia Pacific is expected to experience the fastest growth.

Looking ahead, the combination of AI, PBPK modeling, QSP, pharmacometrics, molecular modeling, virtual patient simulations, and high-performance computing will increasingly transform how pharmaceutical companies discover, develop, and optimize new therapies.

Biosimulation is therefore emerging not simply as a computational support tool, but as an increasingly important component of faster, more efficient, data-driven, and model-informed drug development.

Inquire Before Buying

Share this post:

Recent Posts

Comments are closed.